NemaGen Discoveries is an early phase biotech company focused on advancing therapies for patients suffering from allergic inflammation and mast cell-related diseases.
NemaGen's novel technologies were developed by investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. By taking this unique approach NemaGen has pioneered new therapeutic strategies to help patients suffering from diverse inflammatory diseases.
To further support our drug development, NemaGen will be participating in the NIH I-Corps program March-April 2023 to speak with various stakeholders to better understand their needs and validate our therapy's value.
Please email us for more information regarding our novel technologies or exciting employment opportunities.